Notice of stabilization-like transactions in relation to SciBase Holding AB (publ)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG,
JAPAN, SWITZERLAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE,
PUBLICATION OR DISTRIBUTION IS UNLAWFUL.
Pareto Securities has exercised the possibility to, in connection with the
initial public offering of SciBase Holding AB (publ) (“SciBase”), carry out
stabilization-like transactions.

All stabilization-like transactions were carried out between June 2, 2015 and
June 10, 2015 in the price interval of SEK 44.6 to SEK 50.0. The period for
stabilization-like transactions has now ended and no further stabilization-like
transactions will be carried out.

Interval per day

+-------------+-------------+
|Date         |Interval     |
+-------------+-------------+
|June 2, 2015 |SEK 47.5–50.0|
+-------------+-------------+
|June 3, 2015 |SEK 48.4–49.3|
+-------------+-------------+
|June 4, 2015 |SEK 47.3–49.5|
+-------------+-------------+
|June 5, 2015 |SEK 47.5–48.5|
+-------------+-------------+
|June 8, 2015 |SEK 47.1–47.8|
+-------------+-------------+
|June 9, 2015 |SEK 44.8–46.8|
+-------------+-------------+
|June 10, 2015|SEK 44.6–46.2|
+-------------+-------------+

A total of 495,000 shares in SciBase that Pareto Securities borrowed from SEB
Venture Capital, SEB Pensionsstiftelse and Fouriertransform Aktiebolag have been
returned.

For further information please visit www.scibase.com or contact:

Simon Grant, CEO
Tel: +46 72 887 43 99
E-mail: simon.grant@scibase.com

About Skin Cancer

Skin cancer is one of the most common cancers in the world, accounting for
nearly half of all cancers. It has been estimated that nearly half of all
Americans who live to age 65 will develop skin cancer at least once. Malignant
melanoma is the most fatal form of skin cancer causing the majority (75%) of
deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new
cases of melanoma yearly.

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB").
Avanza is Certified Adviser. Further information is available on
www.scibase.com.

IMPORTANT NOTICE

This announcement is not and does not form a part of any offer for sale of
securities.

Copies of this announcement are not being made and may not be distributed or
sent into the United States, Australia, Canada, New Zealand, Hong Kong, Japan,
Switzerland, South Africa or any other jurisdiction in which such distribution
would be unlawful or would require registration or other measures. The
securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the “Securities
Act”), and accordingly may not be offered or sold in the United States absent
registration or an exemption from the registration requirements of the
Securities Act and in accordance with applicable U.S. state securities laws. The
Company does not intend to register any offering in the United States or to
conduct a public offering of securities in the United States.

Any offering of the securities referred to in this announcement will be made by
means of a prospectus. This announcement is not a prospectus for the purposes of
Directive 2003/71/EC (together with any applicable implementing measures in any
Member State, the “Prospectus Directive”). Investors should not invest in any
securities referred to in this announcement except on the basis of information
contained in the aforementioned prospectus.

In any EEA Member State other than Sweden that has implemented the Prospectus
Directive, this communication is only addressed to and is only directed at
qualified investors in that Member State within the meaning of the Prospectus
Directive, i.e., only to investors who can receive the offer without an approved
prospectus in such EEA Member State.

This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as “relevant persons”). This communication must not be acted
on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only to
relevant persons and will be engaged in only with relevant persons. Persons
distributing this communication must satisfy themselves that it is lawful to do
so.

Matters discussed in this announcement may constitute forward-looking
statements. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date, and are
subject to change without notice.